January 10, 2018 / 8:23 AM / a year ago

BRIEF-Staidson Beijing BioPharmaceuticals sees FY 2017 net profit could rise up to 5 pct

Jan 10 (Reuters) - Staidson Beijing BioPharmaceuticals Co Ltd

* Says it sees FY 2017 net profit could rise by up to 5 percent, or to be 257.3 million yuan to 270.1 million yuan

* Says the net profit of FY 2016 was 257.3 million yuan

* Comments that increased income of polyethylene glycol electrolyte as main reason for the forecast

Source text in Chinese:goo.gl/Rtxod1

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below